Crohn disease (CD) can involve physical, psychological, and social impairments that negatively impact patients’ quality of life, and high levels of anxiety and depression have been observed in patients with CD.
Crohn disease (CD) can involve physical, psychological, and social impairments that negatively impact patients’ quality of life, and high levels of anxiety and depression have been observed in patients with CD. A study in Chinese patients, recently published in Patient Preference and Adherence, sought to evaluate changes in illness perceptions, coping strategies, psychological well-being, and quality of life in patients newly diagnosed with CD and treated with infliximab, and found that effective therapy led to both remission of CD and improved psychological status.
The researchers followed 82 patients with CD who were newly diagnosed between September 2014 and December 2016. Disease severity was evaluated using the Harvey—Bradshaw Index (HBI), and patients also answered 4 questionnaires: the Brief Illness Perceptions Questionnaire, the Brief Coping Operations Preference Enquiry, the Hospital Anxiety and Depression Scale, and the Inflammatory Bowel Disease Questionnaire.
With infliximab treatment, 59 patients (72%) achieved clinical remission at week 14, and patients’ responses to the above questionnaires demonstrated significant improvements in illness perceptions, maladaptive coping, anxiety, depression, and quality of life. By week 30, 58 patients (70.7%) achieved clinical remission, and also reported significant improvements in illness perceptions, maladaptive coping, anxiety, depression, and quality of life versus baseline. Emotion-focused coping and problem-focused coping remained unchanged at weeks 14 and 30 from baseline, however.
For the patients who did not achieve clinical remission with infliximab treatment, psychological characteristics did not show any significant improvement after treatment.
The findings on maladaptive coping, say the authors, are notable because previous longitudinal research on patients with inflammatory bowel disease have shown that maladaptive coping did not change over time with treatment, but most patients in a prior study did not receive infliximab or another anti—tumor necrosis factor therapies, but instead were treated mainly with 5-aminosalicylic acid and immunomodulators. The rapid and effective treatment with infliximab, they suggest, may explain why patients in the current study had better improvement and adopted fewer maladaptive strategies.
While the researchers acknowledge that their study was limited by the fact that HBI (rather than mucosal healing) was used to gauge remission, the findings of this study, say the authors, suggest that interventions that help to reduce a patient’s disease activity may also help to improve psychological characteristics.
Reference
Zhang M, Zhang T, Hong L, et al. Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease. Patient Prefer Adherence. 2018;12:879-885. doi: 10.2147/PPA.S156883.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).